Musulju improves benign prostatic hyperplasia by regulating inflammatory and apoptotic proteins

Ju,Jae‑Yun; Chung,Kyung‑Sook; Cheon,Se‑Yun; An,Hyo‑Jin

doi:10.3892/mmr.2016.5839

Musulju improves benign prostatic hyperplasia by regulating inflammatory and apoptotic proteins

Authors:
- Jae‑Yun Ju
- Kyung‑Sook Chung
- Se‑Yun Cheon
- Hyo‑Jin An
View Affiliations

Affiliations: Department of Pharmacology, College of Korean Medicine, Sangji University, Wonju‑si, Gangwon‑do 220‑702, Republic of Korea
Published online on: October 12, 2016 https://doi.org/10.3892/mmr.2016.5839
Pages: 4692-4698
Copyright: © Ju et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alternative medicine is a widely accepted therapeutic approach for the management of various diseases. The Korean medicine, musulju (MSJ), has been traditionally used to improve vital energy in men with reduced physical strength and a weakened urinary system. The present study determined the mechanisms underlying the protective effect of MSJ against benign prostatic hyperplasia (BPH), a common disorder in elderly men that involves inflammation‑mediated imbalance between cell proliferation and death. MSJ treatment was demonstrated to decrease prostate weight, cell proliferation, and the protein expression of proliferating cell nuclear antigen in a rat model of BPH. In addition, MSJ markedly reduced serum testosterone levels, 5α‑reductase2 mRNA expression and BPH‑associated upregulation of inflammatory proteins, inducible nitric oxide synthase and cyclooxygenase 2. Furthermore, MSJ induced apoptosis by regulating B‑cell lymphoma (Bcl)‑2 protein expression and the Bcl‑2:Bax ratio, leading to caspase 3 activation. Taken together, MSJ demonstrated antiproliferative effects in BPH model rats by regulating the expression levels of proteins involved in inflammation and apoptosis. The effects of MSJ may be attributed to its alternative therapeutic properties.

View Figures

View References

1	Roehrborn CG: Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 95:87–100. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ho CK and Habib FK: Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol. 8:29–41. 2011. View Article : Google Scholar : PubMed/NCBI
3	Huggins C and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 168:9–12. 2002. View Article : Google Scholar : PubMed/NCBI
4	Izumi K, Li L and Chang C: Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. Clin Investig (Lond). 4:935–950. 2014. View Article : Google Scholar : PubMed/NCBI
5	Kramer G, Mitteregger D and Marberger M: Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 51:1202–1216. 2007. View Article : Google Scholar : PubMed/NCBI
6	Shoskes DA: Phytotherapy in chronic prostatitis. Urology. 60:(Suppl 6). S35–S37; discussion 37. 2002. View Article : Google Scholar
7	Hirsch IH: Integrative urology: A spectrum of complementary and alternative therapy. Urology. 56:185–189. 2000. View Article : Google Scholar : PubMed/NCBI
8	Guo QL, Ding QL and Wu ZQ: Effect of baicalein on experimental prostatic hyperplasia in rats and mice. Biol Pharm Bull. 27:333–337. 2004. View Article : Google Scholar : PubMed/NCBI
9	Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, Vidaurre I, Perez R, Halmos G and Szalontay L: Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci USA. 108:3755–3760. 2011. View Article : Google Scholar : PubMed/NCBI
10	Maggi CA, Manzini S, Giuliani S and Meli A: Infravesical outflow obstruction in rats: A comparison of two models. Gen Pharmacol. 20:345–349. 1989. View Article : Google Scholar : PubMed/NCBI
11	Marinese D, Patel R and Walden PD: Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate. 54:230–237. 2003. View Article : Google Scholar : PubMed/NCBI
12	Miller J and Tarter TH: Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. Clin Interv Aging. 4:251–258. 2009.PubMed/NCBI
13	Wei JT, Calhoun E and Jacobsen SJ: Urologic diseases in America project: Benign prostatic hyperplasia. J Urol. 173:1256–1261. 2005. View Article : Google Scholar : PubMed/NCBI
14	Izumi K, Mizokami A, Lin WJ, Lai KP and Chang C: Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol. 182:1942–1949. 2013. View Article : Google Scholar : PubMed/NCBI
15	Pawlicki B, Zielinski H and Dabrowski M: Role of apoptosis and chronic prostatitis in the pathogenesis of benign prostatic hyperplasia. Pol Merkur Lekarski. 17:307–310. 2004.(In Polish). PubMed/NCBI
16	Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S and Maggi M: Benign prostatic hyperplasia: A new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014:329–456. 2014. View Article : Google Scholar
17	Carson C III and Rittmaster R: The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 61(4): Suppl 1. S2–S7. 2003. View Article : Google Scholar
18	Steers WD: 5alpha-reductase activity in the prostate. Urology. 58(6): Suppl 1. S17–S24; discussion 24. 2001. View Article : Google Scholar
19	Meyer-Siegler KL and Vera PL: Substance P induced release of macrophage migration inhibitory factor from rat bladder epithelium. J Urol. 171:1698–1703. 2004. View Article : Google Scholar : PubMed/NCBI
20	Zhang X, Zhang Q, Zhang Z, Na Y and Guo Y: Apoptosis profiles in benign prostatic hyperplasia: Close associations of cell kinetics with percent area density of histologic composition. Urology. 68:905–910. 2006. View Article : Google Scholar : PubMed/NCBI
21	Nuñez G, Benedict MA, Hu Y and Inohara N: Caspases: The proteases of the apoptotic pathway. Oncogene. 17:3237–3245. 1998. View Article : Google Scholar : PubMed/NCBI